top of page
Search

Inhaled Biologics Market Size, Share, Demand & Trends Forecast 2034

  • Writer: Pallavi Garudkar
    Pallavi Garudkar
  • Apr 9
  • 3 min read
Inhaled Biologics Market
Inhaled Biologics Market

According to Fortune Business Insights the global inhaled biologics market size was valued at USD 1.86 billion in 2025. The market is projected to grow from USD 2.10 billion in 2026 to USD 6.15 billion by 2034, exhibiting a CAGR of 14.36% during the forecast period. Inhaled (Inhalable) Biologics are biopharmaceutical drugs (such as proteins, peptides, monoclonal antibodies, and nucleic acids) delivered directly into the lungs via inhalation devices like dry powder inhalers (DPIs), nebulizers, and metered-dose inhalers (MDIs).

These therapies are designed for localized treatment of respiratory diseases and systemic delivery, offering a non-invasive alternative to injections.

Market Segmentation

By Biologic Type

  • Peptides & Proteins

    • Dominant segment (~largest share)

    • Widely used in respiratory and metabolic diseases

  • Monoclonal Antibodies

    • Growing use in targeted therapies (e.g., lung diseases, cancer)

  • RNAi-based Therapeutics

    • Fastest-growing segment due to precision medicine advancements

By Application

  • Respiratory Diseases (Asthma, COPD, Cystic Fibrosis)

    • Largest application segment

  • Diabetes

    • Growing use of inhalable insulin

  • Cancer

    • Emerging segment with targeted biologics

By Distribution Channel

  • Hospital Pharmacies

    • Dominant due to biologics administration

  • Retail Pharmacies

    • Growing with chronic disease management

  • Online Pharmacies

    • Emerging channel driven by digital healthcare

Regional Analysis

North America

  • Largest market share (~leading region)

  • Strong presence of biotech companies and advanced healthcare infrastructure

Europe

  • Significant growth driven by clinical research and regulatory support

  • Strong adoption in Germany, UK, and France

Asia Pacific

  • Fastest-growing region

  • Increasing healthcare investments and large patient population

  • India expected to register highest CAGR

Latin America

  • Moderate growth due to improving healthcare infrastructure

Middle East & Africa

  • Emerging adoption with rising awareness and investments

Competitive Analysis

The inhaled biologics market is highly innovation-driven, with companies focusing on:

  • Development of advanced pulmonary drug delivery systems

  • Strategic collaborations between biotech and pharmaceutical firms

  • Investment in clinical trials and regulatory approvals

  • Focus on precision medicine and targeted therapies

Key Players

  • Hoffmann-La Roche Ltd (Switzerland)

  • Inhalon Biopharma, Inc. (U.S.)

  • Shanghai Novamab Biopharmaceuticals Co., Ltd (China)

  • Aridis Pharmaceuticals, Inc. (U.S.)

  • AptarGroup, Inc. (U.S.)

  • Cambridge Healthcare Innovations (U.K.)

  • Resyca B.V. (Netherlands)

Key Insights

  • Market expected to grow USD 6.15 billion by 2034

  • Peptides & proteins segment dominates

  • North America leads, while Asia Pacific shows fastest growth

  • Shift toward needle-free biologics and precision medicine

  • Strong pipeline of innovative inhalable therapies

Key Industry Development

  • November 2025: Synairgen Research Limited partnered with Aerogen Ltd. to develop and deliver a custom aerosol device for Synairgen's investigational therapy, SNG001 (inhaled interferon-beta). The collaboration brought together Aerogen's aerosol platform and manufacturing expertise with Synairgen's drug development programme, providing targeted respiratory treatment for patients with severe viral infections.

  • October 2025: MannKind Corporation received approval for its supplemental biologics license application (sBLA) from the U.S. FDA for Afrezza (insulin human) Inhalation Powder in children and adolescents living with type 1 or type 2 diabetes.

About Us:

Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them to address various challenges distinct to their businesses. Our aim is to empower them with holistic market intelligence, providing a granular overview of the market they are operating in.

Contact Us:

Fortune Business Insights Pvt. Ltd.

9th Floor, Icon Tower,

Baner - Mahalunge Road, Baner,

Pune-411045, Maharashtra, India.

Phone:

US: +18339092966

UK: +448085020280

APAC: +91 744 740 1245Email: sales@fortunebusinessinsights.com


 
 
 

Comments

bottom of page